La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Imugene Crescita futura

Future criteri di controllo 3/6

Imugene prevede che gli utili e i ricavi cresceranno rispettivamente di 50.7% e 55.2% all'anno. Si prevede che l'EPS crescerà di 51.6% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -63.5% in 3 anni.

Informazioni chiave

58.1%

Tasso di crescita degli utili

58.6%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	14.6%
Tasso di crescita dei ricavi	57.3%
Rendimento futuro del capitale proprio	-66.0%
Copertura analitica	Low
Ultimo aggiornamento	07 Aug 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Nov 11

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Aug 22

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Feb 28

A Look At Imugene's (ASX:IMU) CEO Remuneration

Feb 17

Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

Dec 24

Previsioni di crescita degli utili e dei ricavi

ASX:IMU - Stime future degli analisti e dati finanziari passati (AUD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2027	317	151	N/A	N/A	1
6/30/2026	44	-67	-34	-34	2
6/30/2025	N/A	-98	-54	-54	2
6/30/2024	-7	-150	-111	-102	N/A
3/31/2024	4	-119	-92	-81	N/A
12/31/2023	15	-89	-73	-61	N/A
9/30/2023	13	-64	-52	-46	N/A
6/30/2023	12	-38	-31	-31	N/A
3/31/2023	12	-39	-37	-37	N/A
12/31/2022	12	-40	-42	-42	N/A
9/30/2022	13	-39	-36	-36	N/A
6/30/2022	13	-38	-31	-31	N/A
3/31/2022	11	-33	-27	-25	N/A
12/31/2021	8	-27	-24	-20	N/A
9/30/2021	8	-23	-21	-16	N/A
6/30/2021	7	-18	-19	-13	N/A
3/31/2021	7	-15	-16	-12	N/A
12/31/2020	6	-12	-12	-11	N/A
9/30/2020	5	-11	-12	-11	N/A
6/30/2020	4	-11	-12	-10	N/A
3/31/2020	5	-10	-11	-10	N/A
12/31/2019	5	-9	-10	-9	N/A
9/30/2019	5	-8	-9	-8	N/A
6/30/2019	4	-8	-8	-8	N/A
3/31/2019	3	-7	-7	-7	N/A
12/31/2018	3	-6	-7	-6	N/A
9/30/2018	2	-5	-6	-5	N/A
6/30/2018	2	-4	-5	-5	N/A
3/31/2018	1	-3	N/A	-4	N/A
12/31/2017	1	-3	N/A	-3	N/A
9/30/2017	1	-3	N/A	-3	N/A
6/30/2017	1	-3	N/A	-3	N/A
3/31/2017	1	-3	N/A	-3	N/A
12/31/2016	2	-3	N/A	-3	N/A
9/30/2016	2	-3	N/A	-3	N/A
6/30/2016	2	-3	N/A	-3	N/A
3/31/2016	1	-3	N/A	-2	N/A
12/31/2015	1	-2	N/A	-2	N/A
9/30/2015	1	-2	N/A	-2	N/A
6/30/2015	1	-2	N/A	-2	N/A
3/31/2015	1	-2	N/A	-2	N/A
12/31/2014	1	-2	N/A	-2	N/A
9/30/2014	1	-2	N/A	-1	N/A
6/30/2014	1	-2	N/A	-1	N/A
3/31/2014	0	-2	N/A	-1	N/A
12/31/2013	0	-2	N/A	-1	N/A
9/30/2013	0	-2	N/A	-1	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che IMU diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 2.4% ).

Guadagni vs Mercato: Si prevede che IMU diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede IMU diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che IMU non avrà alcun fatturato il prossimo anno.

Ricavi ad alta crescita: Si prevede che IMU non avrà alcun fatturato il prossimo anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che IMU non sarà più redditizia tra 3 anni.

Imugene Crescita futura

Future criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Forecast to breakeven in 2027

Price target decreased by 8.2% to AU$0.34

No longer forecast to breakeven

Price target decreased by 14% to AU$0.42

Price target decreased by 14% to AU$0.42

Forecast to breakeven in 2026

Recent updates

New minor risk - Financial position

Is Imugene (ASX:IMU) In A Good Position To Invest In Growth?

Forecast to breakeven in 2027

Executive Chairman recently sold AU$1.1m worth of stock

Imugene Limited Announce Enrolment Opened for Its Expansion Study in Bile Tract Cancer (Cholangiocarcinoma) Patients

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Imugene Limited Announces Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment

Price target decreased by 8.2% to AU$0.34

New minor risk - Share price stability

Imugene Limited, Annual General Meeting, Nov 30, 2023

New minor risk - Profitability

No longer forecast to breakeven

Price target decreased by 14% to AU$0.42

Less than half of directors are independent

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Price target decreased by 14% to AU$0.42

Imugene Limited Appoints Paul Woodard as Chief Medical Officer

Imugene Limited Appoints John Byon as Senior Vice President of Clinical Development

Imugene Limited Appoints Dr Bradley Glover as Chief Operating Officer

Imugene Appoints Dr Weitzman Interim Chief Medical Officer

Forecast to breakeven in 2026

Imugene Limited Announces Board Changes

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Price target decreased by 9.8% to AU$0.46

Imugene Limited Announces VAXINIA Trial Advances to Combination Cohort 1 & Monotherapy Cohort 3

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Imugene Limited Receives Vaxinia Ethics Approval in Australia

Imugene Limited Presents New and First CHECKvacc Data At the 2022 San Antonio Breast Cancer Symposium

Imugene Limited Announces First Patient Dosed in VAXINIA Intravenous Cohort 2

Insufficient new directors

Price target decreased to AU$0.52

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA

Independent Non-Executive Director exercised options to buy AU$3.2m worth of stock.

Imugene Limited Announces That First Patient Dosed in VAXINIA Intratumoral Cohort 2

Imugene Limited, Annual General Meeting, Nov 17, 2022

Price target decreased to AU$0.51

Imugene Limited Announces First patient IV dosed in VAXINIA Phase 1 clinical trial

Imugene Limited Announces That Australian Government's Office of the Gene Technology Regulator (Ogtr) Has Granted Imugene the Dir Licence Required to Expand Its Vaxinia Phase 1 Clinical Trial Within Australia

Consensus forecasts updated

Price target decreased to AU$0.52

Imugene Limited Doses First Patient in nextHERIZON Phase 2 Trial

Imugene Appoints Jakob Dupont as Non- Executive Director

Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Imugene Limited Announces First Cohort 3 Patient Dosed in Clinical Trial of CHECKvacc

Imugene Limited Appoints Mike Tonroe as Chief Financial Officer, Effective from September 2022

Imugene Limited Announces Appointment of Dr. Sharon Yavrom as Executive Director, Clinical Scientist

Imugene Limited Announces Final HER-Vaxx Phase 2 Trial Overall Survival Results

Consensus forecasts updated

Independent Non-Executive Director exercised options to buy AU$1.5m worth of stock.

Imugene Limited Announces Board Changes

City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors

Imugene Limited Receives Ethics Approval to Start Phase 2 nextHERIZON Clinical Trial of Cancer Immunotherapy HER-VAXX

Imugene Limited Announces First Cohort 2 Patient Dosed in Clinical Trial of CHECKvacc

Consensus forecasts updated

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Imugene Limited Announces Appointment of Steven Cha as Chief Medical Officer and Member of the Executive Management Team

Imugene Limited Receives Notice of Grant from the European Patent Office for Patent Application Number

Imugene Completes Phase 1a Monotherapy Dose Escalation of Immunotherapy PD1-Vaxx

Executive Chairman recently sold AU$37m worth of stock

Imugene Limited Receives US Food and Drug Administration (FDA) Investigational New Drug (IND) Approval to Initiate A Phase I Clinical Trial of its Oncolytic Virotherapy Candidate, Vaxinia (CF33-hNIS, HOV2)

Imugene Limited Provides Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc

Insider recently sold AU$1.4m worth of stock

Imugene Limited Provides Phase 1 Clinical Trial Update of Its Immunotherapy Pd1-Vaxx

Imugene Presents HER-Vaxx Update at ESMO World GI Congress

Imugene Limited Announces FDA IND Approval of New Oncolytic Virotherapy Checkvacc Virotherapy Checkvacc

CEO, MD & Executive Director exercised options and sold AU$1.6m worth of stock

Independent Non-Executive Director recently sold AU$1.2m worth of stock